AZN News and Press, AstraZeneca PLC From 04/05/24

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful ...

2024-04-04 08:20:35 ET More on CureVac BV CureVac: No Momentum In Sight Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV Read the full article on Seeking Alpha For f...

2024-04-02 08:16:01 ET AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo’s ( OTCPK:DSNKY ) ( OTCPK:DSKYF ) biologics license application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for patients with previously treated metastatic HR-posit...

Application based on results from the TROPION-Breast01 Phase III trial Additional BLA under review in the US for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for patients with advanced nonsquamous non-small cell lung cancer AstraZeneca and Daiichi Sankyo&...

Application based on results from the TROPION-Breast01 phase 3 trial Additional BLA under review in the U.S. for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan for patients with advanced nonsquamous non-small cell lung cancer Daiichi Sankyo (TSE: 4568) and AstraZenec...

2024-04-01 14:26:55 ET More on AstraZeneca What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript Japan approves AstraZeneca-Sanofi drug...

Approval of first-in-class, oral, Factor D inhibitor based on results from pivotal ALPHA Phase III trial VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal ...

2024-04-01 06:08:19 ET Summary Cytokinetics' stock has seen much buyout speculation in recent months, with companies like Eli Lilly, Novartis, Johnson & Johnson, Amgen, and AstraZeneca being potential suitors. The company's Phase 3 study for aficamten, a treatment for heart di...

2024-03-27 07:03:30 ET Beyfortus (nirsevimab), a single-dose monoclonal antibody developed and commercialized in partnership by AstraZeneca ( NASDAQ: AZN ) and Sanofi ( NASDAQ: SNY ), has been approved in Japan for the prevention of lower respiratory tract disease (LRTD) cau...

2024-03-26 07:37:54 ET More on Viking Therapeutics Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeutics: Here To Stay In Obesity, Or A Flash In The Pan? Viking Therapeutics: VK2735 Data Supports A Buyout Jefferies start...